Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Photoaffinity labeling of P450Cam by an imidazole-tethered benzophenone probe.

Trnka MJ, Doneanu CE, Trager WF.

Arch Biochem Biophys. 2006 Jan 1;445(1):95-107. Epub 2005 Nov 14.

PMID:
16321358
2.

Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors.

Suzuki H, Kneller MB, Rock DA, Jones JP, Trager WF, Rettie AE.

Arch Biochem Biophys. 2004 Sep 1;429(1):1-15.

PMID:
15288804
4.

Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition.

Neal JM, Kunze KL, Levy RH, O'Reilly RA, Trager WF.

Drug Metab Dispos. 2003 Aug;31(8):1043-8.

PMID:
12867493
5.

Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.

Yao C, Kunze KL, Trager WF, Kharasch ED, Levy RH.

Drug Metab Dispos. 2003 May;31(5):565-71.

PMID:
12695344
6.

Characterization of covalent adducts to intact cytochrome P450s by mass spectrometry.

Lightning LK, Trager WF.

Methods Enzymol. 2002;357:296-300. No abstract available.

PMID:
12424919
7.

Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.

Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin CR, Doose DR, Gisclon LG, Bialer M.

Epilepsia. 2002 Jul;43(7):691-6. Erratum in: Epilepsia 2002 Oct;43(10):1273.

8.

(+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19.

Suzuki H, Kneller MB, Haining RL, Trager WF, Rettie AE.

Drug Metab Dispos. 2002 Mar;30(3):235-9.

PMID:
11854139
9.

Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.

Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, Levy RH.

Clin Pharmacol Ther. 2001 Nov;70(5):415-24.

PMID:
11719727
10.

Active site characteristics of CYP4B1 probed with aromatic ligands.

Henne KR, Fisher MB, Iyer KR, Lang DH, Trager WF, Rettie AE.

Biochemistry. 2001 Jul 24;40(29):8597-605.

PMID:
11456500
11.

Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s.

He M, Rettie AE, Neal J, Trager WF.

Drug Metab Dispos. 2001 May;29(5):701-11.

PMID:
11302937
12.

A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.

Rao S, Aoyama R, Schrag M, Trager WF, Rettie A, Jones JP.

J Med Chem. 2000 Jul 27;43(15):2789-96.

PMID:
10956186
13.

Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394.

Lightning LK, Jones JP, Friedberg T, Pritchard MP, Shou M, Rushmore TH, Trager WF.

Biochemistry. 2000 Apr 18;39(15):4276-87.

PMID:
10757976
14.

Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ.

Drug Metab Dispos. 1999 Dec;27(12):1488-95.

PMID:
10570031
15.

Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.

He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF.

Arch Biochem Biophys. 1999 Dec 1;372(1):16-28.

PMID:
10562412
16.

Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.

Haining RL, Jones JP, Henne KR, Fisher MB, Koop DR, Trager WF, Rettie AE.

Biochemistry. 1999 Mar 16;38(11):3285-92.

PMID:
10079071
17.

Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9.

Koenigs LL, Peter RM, Hunter AP, Haining RL, Rettie AE, Friedberg T, Pritchard MP, Shou M, Rushmore TH, Trager WF.

Biochemistry. 1999 Feb 23;38(8):2312-9.

PMID:
10029524
18.
19.

Mechanism-based inactivation of P450 2A6 by furanocoumarins.

Koenigs LL, Trager WF.

Biochemistry. 1998 Jul 14;37(28):10047-61.

PMID:
9665710
20.

(R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6.

Khojasteh-Bakht SC, Koenigs LL, Peter RM, Trager WF, Nelson SD.

Drug Metab Dispos. 1998 Jul;26(7):701-4.

PMID:
9660853
21.

Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6.

Chen W, Koenigs LL, Thompson SJ, Peter RM, Rettie AE, Trager WF, Nelson SD.

Chem Res Toxicol. 1998 Apr;11(4):295-301.

PMID:
9548799
22.

Lack of effect of azelastine and ketoconazole coadministration on electrocardiographic parameters in healthy volunteers.

Morganroth J, Lyness WH, Perhach JL, Mather GG, Harr JE, Trager WF, Levy RH, Rosenberg A.

J Clin Pharmacol. 1997 Nov;37(11):1065-72.

PMID:
9506001
23.

Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.

Koenigs LL, Peter RM, Thompson SJ, Rettie AE, Trager WF.

Drug Metab Dispos. 1997 Dec;25(12):1407-15.

PMID:
9394031
24.

Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants.

Tran A, Rey E, Pons G, Rousseau M, d'Athis P, Olive G, Mather GG, Bishop FE, Wurden CJ, Labroo R, Trager WF, Kunze KL, Thummel KE, Vincent JC, Gillardin JM, Lepage F, Levy RH.

Clin Pharmacol Ther. 1997 Nov;62(5):490-504.

PMID:
9390105
25.

Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE.

Pharmacogenetics. 1997 Oct;7(5):361-7.

PMID:
9352571
28.

Substrate probe for the mechanism of aromatic hydroxylation catalyzed by cytochrome P450.

Darbyshire JF, Iyer KR, Grogan J, Korzekwa KR, Trager WF.

Drug Metab Dispos. 1996 Sep;24(9):1038-45.

PMID:
8886617
29.

Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.

Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF.

Drug Metab Dispos. 1996 May;24(5):610-4.

PMID:
8723744
30.
31.

Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.

Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, Evans JS, Bauwens JE, Trager WF.

Drug Metab Dispos. 1996 Apr;24(4):422-8.

PMID:
8801057
32.

Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.

Kunze KL, Wienkers LC, Thummel KE, Trager WF.

Drug Metab Dispos. 1996 Apr;24(4):414-21.

PMID:
8801056
33.

Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9.

Jones JP, He M, Trager WF, Rettie AE.

Drug Metab Dispos. 1996 Jan;24(1):1-6. No abstract available.

PMID:
8825183
35.

Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites.

He M, Kunze KL, Trager WF.

Drug Metab Dispos. 1995 Jun;23(6):659-63.

PMID:
7587949
36.

Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism.

Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED.

Drug Metab Dispos. 1995 Apr;23(4):490-6.

PMID:
7600917
37.

Isotope effect studies on the cytochrome P450 enzymes.

Korzekwa KR, Gillette JR, Trager WF.

Drug Metab Rev. 1995;27(1-2):45-59. Review.

PMID:
7641584
38.

Application of negative-ion chemical ionization isotope dilution gas chromatography--mass spectrometry to single-dose bioavailability studies of mefloquine.

Neal JM, Howald WN, Kunze KL, Lawrence RF, Trager WF.

J Chromatogr B Biomed Appl. 1994 Nov 18;661(2):263-9.

PMID:
7894666
39.

Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.

Hall SD, Hamman MA, Rettie AE, Wienkers LC, Trager WF, Vandenbranden M, Wrighton SA.

Drug Metab Dispos. 1994 Nov-Dec;22(6):975-8. No abstract available.

PMID:
7895619
40.

Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.

Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, Perkins JD, et al.

J Pharmacol Exp Ther. 1994 Oct;271(1):557-66.

PMID:
7965756
41.

Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.

Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, et al.

J Pharmacol Exp Ther. 1994 Oct;271(1):549-56.

PMID:
7965755
42.
43.

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR.

Pharmacogenetics. 1994 Feb;4(1):39-42. No abstract available.

PMID:
8004131
44.

Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis.

O'Sullivan TA, Wang JP, Unadkat JD, al-Habet SM, Trager WF, Smith AL, McNamara S, Aitken ML.

Clin Pharmacol Ther. 1993 Sep;54(3):323-8.

PMID:
8375128
45.

Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline.

Kunze KL, Trager WF.

Chem Res Toxicol. 1993 Sep-Oct;6(5):649-56.

PMID:
8292742
46.

Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference.

Woolf TF, Pool WF, Bjorge SM, Chang T, Goel OP, Purchase CF 2nd, Schroeder MC, Kunze KL, Trager WF.

Drug Metab Dispos. 1993 Sep-Oct;21(5):874-82.

PMID:
7902251
47.

Studies on the mechanism of aromatase and other cytochrome P450 mediated deformylation reactions.

Korzekwa KR, Trager WF, Mancewicz J, Osawa Y.

J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):367-73. Review.

PMID:
8476750
48.

Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects.

O'Reilly RA, Goulart DA, Kunze KL, Neal J, Gibaldi M, Eddy AC, Trager WF.

Clin Pharmacol Ther. 1992 Jun;51(6):656-67.

PMID:
1611805
49.

The mechanism of the interaction between amiodarone and warfarin in humans.

Heimark LD, Wienkers L, Kunze K, Gibaldi M, Eddy AC, Trager WF, O'Reilly RA, Goulart DA.

Clin Pharmacol Ther. 1992 Apr;51(4):398-407.

PMID:
1563209
50.

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.

Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF.

Chem Res Toxicol. 1992 Jan-Feb;5(1):54-9.

PMID:
1581537

Supplemental Content

Loading ...
Support Center